Ionis down on delay of Huntington’s disease data readout

Ionis Pharmaceuticals (IONS -5.8%) slips on modestly higher volume in apparent reaction to collaboration Roche’s (OTCQX:RHHBY -1.2%) disclosure that an expected data readout from their joint program, in this case a Phase 2 study evaluating RO7234292 (ISIS 443139), in Huntington’s disease will be delayed until late 2020 or early 2021. Previously, Roche indicated that additional data would be available in H1 2020.

The timeline for results from a Phase 3 trial is still on track. If all goes well, marketing applications will be filed in 2022.

https://seekingalpha.com/news/3506184-ionis-6-percent-delay-huntingtons-disease-data-readout